BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25947406)

  • 1. Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Qiao SK; Guo XN; Ren JH; Ren HY
    Chin Med J (Engl); 2015 May; 128(9):1215-22. PubMed ID: 25947406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation.
    McCormack PL
    Drugs Aging; 2015 May; 32(5):409-18. PubMed ID: 25925941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
    McCarthy PL; Holstein SA; Petrucci MT; Richardson PG; Hulin C; Tosi P; Bringhen S; Musto P; Anderson KC; Caillot D; Gay F; Moreau P; Marit G; Jung SH; Yu Z; Winograd B; Knight RD; Palumbo A; Attal M
    J Clin Oncol; 2017 Oct; 35(29):3279-3289. PubMed ID: 28742454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
    Wang Y; Yang F; Shen Y; Zhang W; Wang J; Chang VT; Andersson BS; Qazilbash MH; Champlin RE; Berenson JR; Guan X; Wang ML
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26582244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.
    Yang B; Yu RL; Chi XH; Lu XC
    PLoS One; 2013; 8(5):e64354. PubMed ID: 23691202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: a meta-analysis of 14 randomized controlled trials.
    Wang L; Xu YL; Zhang XQ
    Leuk Lymphoma; 2014 Jul; 55(7):1479-88. PubMed ID: 23998282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
    Syed YY
    Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
    Wang GM; Yang GZ; Huang ZX; Zhong YP; Jin FY; Liao AJ; Wang XM; Fu ZZ; Liu H; Li XL; Zhou JF; Zhang X; Hu Y; Meng FY; Huang XJ; Chen WM; Lu J
    Zhonghua Nei Ke Za Zhi; 2017 Jul; 56(7):500-506. PubMed ID: 28693058
    [No Abstract]   [Full Text] [Related]  

  • 10. Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang L; Ran X; Wang B; Sheng Z; Liu L
    Hematol Oncol; 2012 Jun; 30(2):57-61. PubMed ID: 21809367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
    Zheng Y; Shen H; Xu L; Feng J; Tang H; Zhang N; Chen X; Gao G
    J Immunol Res; 2018; 2018():7646913. PubMed ID: 30050957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials.
    Gao M; Gao L; Yang G; Tao Y; Tompkins VS; Wu X; Xu H; Zhan F; Shi J
    Int J Clin Exp Pathol; 2014; 7(6):3073-80. PubMed ID: 25031726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis.
    Wang X; Li Y; Yan X
    Biomed Res Int; 2016; 2016():6848902. PubMed ID: 26949704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
    Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
    J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma.
    Mian I; Milton DR; Shah N; Nieto Y; Popat UR; Kebriaei P; Parmar S; Oran B; Shah JJ; Manasanch EE; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
    Cancer; 2016 Dec; 122(24):3831-3837. PubMed ID: 27680710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with thalidomide and lenalidomide in multiple myeloma.
    Moehler T
    Curr Cancer Drug Targets; 2012 May; 12(4):372-90. PubMed ID: 22229246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials.
    Gao M; Kong Y; Wang H; Xie B; Yang G; Gao L; Zhang Y; Zhan F; Dai B; Tao Y; Shi J
    Tumour Biol; 2016 Aug; 37(8):11081-98. PubMed ID: 26906553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
    Palumbo A; Bringhen S; Kumar SK; Lupparelli G; Usmani S; Waage A; Larocca A; van der Holt B; Musto P; Offidani M; Petrucci MT; Evangelista A; Zweegman S; Nooka AK; Spencer A; Dimopoulos MA; Hajek R; Cavo M; Richardson P; Lonial S; Ciccone G; Boccadoro M; Anderson K; Barlogie B; Sonneveld P; McCarthy PL
    Lancet Oncol; 2014 Mar; 15(3):333-42. PubMed ID: 24525202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses.
    Aguiar PM; de Mendonça Lima T; Colleoni GWB; Storpirtis S
    Crit Rev Oncol Hematol; 2017 May; 113():195-212. PubMed ID: 28427509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.